SLC35E2 promoter mutation as a prognostic marker of esophageal squamous cell carcinoma

Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell ther…

Source: Yeasen Biotech·https://www.yeasen.com/literature/detail/2071885966792577028

Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals …

Source: Yeasen Biotech·https://www.yeasen.com/literature/detail/2071885966805159947

De novo design of GPCR exoframe modulators

Source: Yeasen Biotech·https://www.yeasen.com/literature/detail/2065008719673470977

Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-med…

Source: Yeasen Biotech·https://www.yeasen.com/literature/detail/2071885966788382722

Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling

Source: Yeasen Biotech·https://www.yeasen.com/literature/detail/2065008739348951043

A broadly protective antibody targeting gammaherpesvirus gB

Source: Yeasen Biotech·https://www.yeasen.com/literature/detail/2065008724417228802

Efficient and precise programmable DNA knock-in without double-strand breaks

Source: Yeasen Biotech·https://www.yeasen.com/literature/detail/2072500662350464805

Single-cell identifies and validates human circulating Treg subtype/state Tregfci in non-s…

Source: Yeasen Biotech·https://www.yeasen.com/literature/detail/2065008694079827969